Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Archer marches towards broad use with biochip advancement
    • News

    Archer marches towards broad use with biochip advancement

    *Owners of this website are shareholders in a company mentioned in this article and have been engaged by them to assist in investor communications

    Read More
    Public
  • APM bags US and Canada contracts worth $150 million, eyes UK for future growth
    • News

    APM bags US and Canada contracts worth $150 million, eyes UK for future growth

    Perth-based human services provider APM (ASX: APM) was born with the desire to help people of all backgrounds land jobs. Turns out, many organisations are on board with this desire seeing as the Company is locking in contracts across the world, with its most recent wins in Canada and the US.  Under the Ontario Employment

    Read More
    Public
  • Pointing to balance sheet woes, Sequoia divests 80% of its stake in Morrison for $40 million
    • News

    Pointing to balance sheet woes, Sequoia divests 80% of its stake in Morrison for $40 million

    Integrated financial services company Sequoia Financial Group Limited (ASX: SEQ) is set to offload 80% of its equity interest in stock broking execution company Morrison Securities to New Quantum Holdings (NQ), a company that provides digital wealth management platform services.  As a result, the Company will receive $40.5 million, giving Morrison a debt-free balance sheet

    Read More
    Public
  • After its past project fell into a slump, Douugh hopes its super app project will jump
    • News

    After its past project fell into a slump, Douugh hopes its super app project will jump

    After two “remarkable” attempts at business expansion, with one landing in hot water with the ASX while the other one completely flopped, shares in wealth management app Douugh (ASX: DOU) remains confident that the glass is still half full because hey, they say third time’s a charm. The Company claimed that its super money app

    Read More
    Public
  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%

    Clinical state oncology company Prescient Therapeutics (ASX: PTX) has received the US FDA’s Orphan Drug Designation for its PTX-100 drug, used for cancer treatment. Previously, the Company received ODD for peripheral T-cell lymphomas (PTCL) in 2022. Following that, it applied for ODD for cutaneous T-cell lymphomas (CTCL), and it was granted a blanket designation for

    Read More
    Public
  • Swift awarded $2 million in contract wins, projects slated for completion in 2023
    • News

    Swift awarded $2 million in contract wins, projects slated for completion in 2023

    Entertainment and tech infrastructure company Swift (ASX: SW1) is making it big in Western Australia, locking in deals worth $2.06 million. It has been awarded projects across multiple sites for market-leading companies, like OTOC, AngloGold Ashanti, Mineral Resources and Roy Hill, due in 2023.  As per the agreements, the Company’s engineering and delivery teams will

    Read More
    Public
  • «
  • ‹
  • 271
  • 272
  • 273
  • 274
  • 275
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.